PharmaShots | Incisive News in 3 Shots

Subscribe Now

Cabaletta Bio

Cabaletta Bio’s CABA-201 Receives the US FDA’s Orphan Drug Designation to Treat Systemic Sclerosis

Cabaletta Bio’s CABA-201 Receives the US FDA’s Orphan Drug Designation to Treat Systemic Sclerosis

March 21, 2024

Cabaletta’s IND Application for CABA-201 Receives the US FDA’s Approval for the Treatment of Generalized Myasthenia Gravis (gMG)

Cabaletta’s IND Application for CABA-201 Receives the US FDA’s Approval for the Treatment of Generalized Myasthenia Gravis (gMG)

November 7, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us